# Genetics Caused It, and the Drug Still Worked

By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-08-20 | Updated: 2026-10-30

Canonical page: https://glpwatchdog.org/research/genetics-caused-it-and-the-drug-still-worked

> MC4R mutations are the most common single genetic cause of obesity, and sit at the center of the brain's appetite pathway. Carriers in SURMOUNT-1 lost 18.3% of their weight against 19.9% in everyone else.

## Key points

- 32 carriers lost 18.3% vs 19.9% in non-carriers over 72 weeks.
- Surprising: MC4R sits at the center of appetite regulation, downstream of leptin.
- Implies the drug works by a route that does not need an intact receptor.
- Thirty-two people, no confidence interval reported, and carriers started heavier.
- Genetics explains why someone has obesity, and currently not which drug will help.

Some obesity has a single identifiable genetic cause, and the commonest is a mutation in the *MC4R* gene, which encodes a receptor at the center of how the brain regulates appetite. Researchers found 32 carriers inside the SURMOUNT-1 trial and looked at what happened to them. They lost **18.3%** of their body weight, against 19.9% in everyone else.[1]

## Why this was not the expected answer

The melanocortin 4 receptor is part of the chain that carries signals about the body’s energy stores into decisions about hunger. Leptin, released from fat tissue, feeds into that pathway; MC4R is downstream of it. When the receptor does not work, the brain does not receive the message that there is enough fuel, and hunger persists.

People with these mutations have historically been difficult to treat, which is why a drug exists specifically for disorders of that pathway. The reasonable prior expectation was that a broken appetite receptor would blunt the effect of an appetite-acting drug.

> The receptor was broken and the drug worked anyway.

That implies tirzepatide reduces appetite by a route that does not depend on an intact MC4R (the routes it does use are set out in [how Zepbound works](https://glpwatchdog.org/research/how-zepbound-works)). That is mechanistically interesting, and for the people concerned it is considerably more useful than interesting. A related expectation, that weight carried since youth should resist the drug, also failed when tirzepatide trials compared [obesity that began before age 25](https://glpwatchdog.org/research/does-a-lifetime-of-it-change-anything) with obesity that began later.

## The numbers, and how many they rest on

*MC4R mutation carriers within SURMOUNT-1.[1]*

|   | Carriers | Non-carriers |
| --- | --- | --- |
| Number | **32** (1.4% of 2,291) | 2,259 |
| Baseline BMI | 40 kg/m² | 38 kg/m² (P = 0.036) |
| Weight reduction at 72 weeks | **18.3%** | **19.9%** |

> **Thirty-two people.** The abstract reports no confidence interval for that 18.3%, and in a group this size it would be wide enough to accommodate a fair range of true values. “Comparable” here means the point estimates landed close together in a comparison that could not have detected a moderate difference if one existed.

It is also a research letter of three pages rather than a full trial report, and the carriers began heavier (a BMI of 40 against 38), which is consistent with a penetrant mutation and is one more way the groups were not identical.

None of that undoes the finding. A 1.6 percentage point gap in a group of 32 is a reasonable basis for saying these patients are not obviously being failed by the drug, which is what people with this diagnosis want to know.

## Two kinds of genetics, one conclusion

This register has now covered genetics in obesity from both ends, and they arrive at the same practical place.

*Rare and common genetic effects, and what each predicts.*

|   | Effect on causing obesity | Effect on drug response |
| --- | --- | --- |
| **Rare, highly penetrant** (MC4R) | Large — a single mutation is sufficient | **Essentially none detected** |
| **Common variants** ([GWAS](https://glpwatchdog.org/research/the-genetics-are-real-and-small)) | Small individually | Real but tiny — about 0.76 kg per allele |

So genetics explains a great deal about *why* someone carries excess weight, and currently very little about *which treatment* will help them. Those are separate questions and they are routinely merged in marketing for genetic tests, which we take apart in [the genetic test that isn’t ready](https://glpwatchdog.org/research/the-genetic-test-that-isnt-ready).

## What it means practically

- **An MC4R diagnosis is not a reason to expect these drugs to fail.** On the only direct evidence available, carriers responded like everyone else.
- **It is 32 people**, so this supports rather than settles.
- **It does not speak to other monogenic causes.** Leptin receptor, POMC and the rest were not examined here.
- **Testing is a clinical decision** with its own reasons, and this finding is not one of them: knowing you carry the mutation would not change which drug to try.

The broader point about who these trials enrolled, and how far their results travel, is in [who was actually in the trials](https://glpwatchdog.org/research/who-was-actually-in-the-trials).

## Frequently asked questions

### Do GLP-1 drugs work if obesity has a genetic cause?

In the one direct examination available, yes. Thirty-two SURMOUNT-1 participants carrying pathogenic MC4R mutations (the most common genetic cause of obesity) lost 18.3% of their weight against 19.9% in non-carriers.

### Why was that surprising?

MC4R sits at the center of the brain pathway that regulates appetite, downstream of leptin signaling, and people with these mutations have historically been hard to treat. The result implies the drug reduces appetite by a route that does not require an intact receptor.

### How solid is the finding?

It rests on 32 carriers, with no confidence interval reported for their result, in a comparison that could not have detected a moderate difference. It supports the conclusion rather than establishing it.

### Does this mean genetics do not affect treatment response?

It means neither kind of genetic effect currently predicts it usefully. Rare penetrant mutations cause obesity without visibly reducing response, and common variants shift expected weight loss by under a kilogram per copy (about 0.76 kg).

### Should someone get tested for MC4R?

That is a clinical decision with its own reasons, and this finding is not one of them, because knowing the result would not change which drug to try.

## References

1. Bhatnagar P, Ahmad NN, Li X, et al. Tirzepatide leads to weight reduction in people with obesity due to MC4R deficiency. Nature Medicine. 2025. PMID: 40858971. https://pubmed.ncbi.nlm.nih.gov/40858971/

---

Cite as: GLP Watchdog, Nora Bissett, "Genetics Caused It, and the Drug Still Worked", published 2026-08-20, updated 2026-10-30. https://glpwatchdog.org/research/genetics-caused-it-and-the-drug-still-worked

Canonical HTML page: https://glpwatchdog.org/research/genetics-caused-it-and-the-drug-still-worked

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.
